Vizsgálati helyszín
Westfaelische Wilhelms-Universitaet Muenster
Muenster, 48149, NémetországMég nincs intézményhez kötve
- 19futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 33 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis9 vizsgálat
- 1/2. fázis4 vizsgálat
- 4. fázis3 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Fut, nem toboroz13 vizsgálat
- Toboroz6 vizsgálat
- Fő szponzor
- Merck Sharp & Dohme LLC4 vizsgálat
- Dr. Inge Winter3 vizsgálat
- Boehringer Ingelheim2 vizsgálat
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)2 vizsgálat
- Sanofi2 vizsgálat
- és még 19
Futó vizsgálatok
Toboroz
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973786· 3. fázis· Dr. Inge Winter· Forrás
Fut, nem toboroz
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Toboroz
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973851· 3. fázis· Dr. Inge Winter· Forrás
Toboroz
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875· 4. fázis· Dr. Inge Winter· Forrás
Toboroz
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775· 1/2. fázis· Miltenyi Biomedicine GmbH· Forrás
Toboroz
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492· 3. fázis· Jena University Hospital· Forrás
Toboroz
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
NCT06482684· 2. fázis· Christian Schmidt, MD· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
NCT05551299· 4. fázis· University of Leipzig· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· 2. fázis· Mirum Pharmaceuticals, Inc.· Forrás
Toboroz
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
2023-504880-18-00· 1/2. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Fut, nem toboroz
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
NCT03206671· 3. fázis· University Hospital Muenster· Forrás
Toboroz
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
2023-504694-20-00· 1/2. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihistamines
2023-505446-25-00· 1/2. fázis· Jasper Therapeutics Inc.· Forrás
Leállították
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-505558-16-00· 3. fázis· Almirall S.A.· Forrás
Lezárult
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· 3. fázis· Amgen Inc.· Forrás
Lezárult
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· 2. fázis· University of Leipzig· Forrás
Lezárult
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· 2. fázis· LEO Pharma· Forrás
Lezárult
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· 2. fázis· Sanofi· Forrás
Lezárult
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365· 3. fázis· Almirall, S.A.· Forrás
Lezárult
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580· 2. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357· 1. fázis· Genmab· Forrás
Fut, nem toboroz
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125· 4. fázis· Bayer· Forrás
Lezárult
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749· 3. fázis· Bristol-Myers Squibb· Forrás
Hibát jelzek